Anti-John Cunningham Virus antibody prevalence in multiple sclerosis patients in Turkey

Year 2014, Volume: 31 Issue: 1, 31 - 36, 05.06.2014

Mefkure Eraksoy Kadriye Agan Fikri Ak Omer Anlar Belgin Balcı Cavit Boz Yahya Celık Seref Demırkaya Husnu Efendı Muhtesem Gecızlıoglu Dilek Gunal Hulya Aydın Gungor Nihal Isık Egemen Idılman Rana Karabudak Aslı Kurne Munife Neyal Serkan Ozakbas Ozgul Ekmekcı Ozbay Cemal Ozcan Nese Oztekın Musa Ozturk Sabahattin Saıp Aksel Sıva Aysun Soysal Ozlem Taskapılıoglu Murat Terzı Omer Turan Recai Turkoglu Nezih Yucemen Ayse Yuceyar Yasar Zorlu Cunay Ulku Huseyin Dıb Deniz Uren

https://izlik.org/JA48ZW63EF

Abstract

Exposure to John Cunningham Virus (JCV) has been associated with Progressive Multifocal Leukoencephalopathy (PML) in Multiple Sclerosis (MS) patients under specific treatments. In order to assess the identifiable risks of Turkish relapsing-remitting multiple sclerosis (RRMS) patients, the seroprevalence rate of JCV antibodies was investigated and compared with demographic and therapy related factors. Serum samples were collected from 308 RRMS patients at 24 centers, and tested by STRATIFY JCV assay for the presence of anti-JCV antibodies. Also, demographic, disease and treatment data were collected at the same time and were used for analysis of associations with seropositivity. The prevalence of anti-JCV antibodies was observed to be 68.2%, which is higher than most countries. There was a trend in terms of higher seroprevalence of antibodies in older patients, and male patients. There was no association with previous
natalizumab use, but there was a significantly higher seroprevalence in patients who used immunosuppressant therapies (p<0.05). JCV prevalence rate is observed to be
high in Turkish MS patients, therefore it would be beneficial to use this marker as a risk stratification tool in clinical decision making.

Keywords

John Cunningham Virus , Multiple Sclerosis , Natalizumab , Turkey

References

Bloomgren, G., Richman, S., Hotermans, C., Subramanyam, M., Goelz, S., Natarajan, A., Lee, S., Plavina, T., Scanlon, J.V., Pharm, D., Sandrock, A., Bozic, C., 2012. Risk of natalizumab associated progressive multifocal leukoencephalopathy. N. Engl. J. Med. 366, 1870-1880. doi: 1056/NEJMoa1107829.
Bozic, C., Richman, S., Plavina, T., Natarajan, A., Scanlon, J.V., Subramanyam, M., Sandrock, A., Bloomgren, G., 2011. Anti-John Cunningham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1. Ann. Neurol. 70, 742-750. doi: 10.1002/ana.22606. Bozic, C., Richman, S., Plavina, T., Natarajan, A., Scanlon, J., Subramanyam, M., Sandrock, A. and Bloomgren, G., 2012. Anti-JCV antibody prevalence in patients with relapsing multiple sclerosis receiving or considering treatment with natalizumab: baseline results of STRATIFY- Neurology. 78, S41.002.
Bozic, C., Subramanyam, M., Paes, D., Richman, S., Plavina, T., Zhang, A., Ticho, B., 2012. Anti-JC virus antibody prevalence in the JCV Epidemiology in MS trial. ECTRIMS, October 10-13, Lyon, France.
Fig. Prevalence of anti-JCV antibodies is higher in the patients who have used immunosuppressant treatments (p<0.05). Fig. Prevalence between the patients exposed to natalizumab (p=0.155).

There are 4 citations in total.

Details

Primary Language	English
Subjects	Health Care Administration
Journal Section	Research Article
Authors	Mefkure Eraksoy This is me Kadriye Agan This is me Fikri Ak This is me Omer Anlar This is me Belgin Balcı This is me Cavit Boz This is me Yahya Celık This is me Seref Demırkaya This is me Husnu Efendı This is me Muhtesem Gecızlıoglu This is me Dilek Gunal This is me Hulya Aydın Gungor This is me Nihal Isık This is me Egemen Idılman This is me Rana Karabudak This is me Aslı Kurne This is me Munife Neyal This is me Serkan Ozakbas This is me Ozgul Ekmekcı Ozbay This is me Cemal Ozcan This is me Nese Oztekın This is me Musa Ozturk This is me Sabahattin Saıp This is me Aksel Sıva This is me Aysun Soysal This is me Ozlem Taskapılıoglu This is me Murat Terzı This is me Omer Turan This is me Recai Turkoglu This is me Nezih Yucemen This is me Ayse Yuceyar This is me Yasar Zorlu This is me Cunay Ulku This is me Huseyin Dıb This is me Deniz Uren This is me
Submission Date	December 16, 2013
Publication Date	June 5, 2014
IZ	https://izlik.org/JA48ZW63EF
Published in Issue	Year 2014 Volume: 31 Issue: 1

Cite

APA	Eraksoy, M., Agan, K., Ak, F., Anlar, O., Balcı, B., Boz, C., Celık, Y., Demırkaya, S., Efendı, H., Gecızlıoglu, M., Gunal, D., Aydın Gungor, H., Isık, N., Idılman, E., Karabudak, R., Kurne, A., Neyal, M., Ozakbas, S., Ekmekcı Ozbay, O., … Uren, D. (2014). Anti-John Cunningham Virus antibody prevalence in multiple sclerosis patients in Turkey. Deneysel Ve Klinik Tıp Dergisi, 31(1), 31-36. https://izlik.org/JA48ZW63EF
AMA	1.Eraksoy M, Agan K, Ak F, et al. Anti-John Cunningham Virus antibody prevalence in multiple sclerosis patients in Turkey. J. Exp. Clin. Med. 2014;31(1):31-36. https://izlik.org/JA48ZW63EF
Chicago	Eraksoy, Mefkure, Kadriye Agan, Fikri Ak, et al. 2014. “Anti-John Cunningham Virus Antibody Prevalence in Multiple Sclerosis Patients in Turkey”. Deneysel Ve Klinik Tıp Dergisi 31 (1): 31-36. https://izlik.org/JA48ZW63EF.
EndNote	Eraksoy M, Agan K, Ak F, Anlar O, Balcı B, Boz C, Celık Y, Demırkaya S, Efendı H, Gecızlıoglu M, Gunal D, Aydın Gungor H, Isık N, Idılman E, Karabudak R, Kurne A, Neyal M, Ozakbas S, Ekmekcı Ozbay O, Ozcan C, Oztekın N, Ozturk M, Saıp S, Sıva A, Soysal A, Taskapılıoglu O, Terzı M, Turan O, Turkoglu R, Yucemen N, Yuceyar A, Zorlu Y, Ulku C, Dıb H, Uren D (June 1, 2014) Anti-John Cunningham Virus antibody prevalence in multiple sclerosis patients in Turkey. Deneysel ve Klinik Tıp Dergisi 31 1 31–36.
IEEE	[1]M. Eraksoy et al., “Anti-John Cunningham Virus antibody prevalence in multiple sclerosis patients in Turkey”, J. Exp. Clin. Med., vol. 31, no. 1, pp. 31–36, June 2014, [Online]. Available: https://izlik.org/JA48ZW63EF
ISNAD	Eraksoy, Mefkure - Agan, Kadriye - Ak, Fikri - Anlar, Omer - Balcı, Belgin - Boz, Cavit - Celık, Yahya et al. “Anti-John Cunningham Virus Antibody Prevalence in Multiple Sclerosis Patients in Turkey”. Deneysel ve Klinik Tıp Dergisi 31/1 (June 1, 2014): 31-36. https://izlik.org/JA48ZW63EF.
JAMA	1.Eraksoy M, Agan K, Ak F, Anlar O, Balcı B, Boz C, Celık Y, Demırkaya S, Efendı H, Gecızlıoglu M, Gunal D, Aydın Gungor H, Isık N, Idılman E, Karabudak R, Kurne A, Neyal M, Ozakbas S, Ekmekcı Ozbay O, Ozcan C, Oztekın N, Ozturk M, Saıp S, Sıva A, Soysal A, Taskapılıoglu O, Terzı M, Turan O, Turkoglu R, Yucemen N, Yuceyar A, Zorlu Y, Ulku C, Dıb H, Uren D. Anti-John Cunningham Virus antibody prevalence in multiple sclerosis patients in Turkey. J. Exp. Clin. Med. 2014;31:31–36.
MLA	Eraksoy, Mefkure, et al. “Anti-John Cunningham Virus Antibody Prevalence in Multiple Sclerosis Patients in Turkey”. Deneysel Ve Klinik Tıp Dergisi, vol. 31, no. 1, June 2014, pp. 31-36, https://izlik.org/JA48ZW63EF.
Vancouver	1.Mefkure Eraksoy, Kadriye Agan, Fikri Ak, Omer Anlar, Belgin Balcı, Cavit Boz, Yahya Celık, Seref Demırkaya, Husnu Efendı, Muhtesem Gecızlıoglu, Dilek Gunal, Hulya Aydın Gungor, Nihal Isık, Egemen Idılman, Rana Karabudak, Aslı Kurne, Munife Neyal, Serkan Ozakbas, Ozgul Ekmekcı Ozbay, Cemal Ozcan, Nese Oztekın, Musa Ozturk, Sabahattin Saıp, Aksel Sıva, Aysun Soysal, Ozlem Taskapılıoglu, Murat Terzı, Omer Turan, Recai Turkoglu, Nezih Yucemen, Ayse Yuceyar, Yasar Zorlu, Cunay Ulku, Huseyin Dıb, Deniz Uren. Anti-John Cunningham Virus antibody prevalence in multiple sclerosis patients in Turkey. J. Exp. Clin. Med. [Internet]. 2014 Jun. 1;31(1):31-6. Available from: https://izlik.org/JA48ZW63EF